BioSpace News Archive

Business

Quarterly Activities and Cashflow Report - Jan 30, 2023

Bionomics Limited, a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, released its Appendix 4C – Quarterly Cashflow Report.

January 30, 2023
·
7 min read
Drug Development

Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China

Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of patient dosing in Phase 3 clinical trials of ecnoglutide (XW003) in adult patients with type 2 diabetes in China.

January 30, 2023
·
3 min read
Drug Development

Qurient Announces Dosing of First Patient in Q702 in Combination with KEYTRUDA® in a Phase 1b/2 Clinical Study for the Treatment of Patients with Solid Tumors

Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the first patient has been dosed in the Phase 1b/2 clinical study of Q702 in combination with KEYTRUDA® (pembrolizumab).

January 30, 2023
·
2 min read
Business

SQI Diagnostics Reports Fourth Quarter and Fiscal 2022 Results

SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.

January 30, 2023
·
6 min read